Table 4

Internal responsiveness of disease activity measures in patients with primary Sjögren's syndrome treated with rituximab

Standardised response mean
Time pointESSPRIESSDAIPatient's GDAPhysician's GDAIgM-RfSWS
Week 16−0.86−1.19−0.97−2.41−0.800.25
Week 24−0.68−0.98−0.73−2.62−0.780.24
Week 36−0.53−0.99−0.94−1.99−0.650.10
Week 48−0.27−0.34−0.83−1.24−0.200.18
Week 60−0.29−0.04−0.49−0.660.10−0.13
Effect size
Time pointESSPRIESSDAIPatient's GDAPhysician's GDAIgM-RfSWS
Week 16−0.77−1.13−1.21−2.36−0.480.15
Week 24−0.66−1.11−0.90−2.65−0.480.19
Week 36−0.55−1.13−1.22−2.41−0.290.09
Week 48−0.25−0.60−0.99−1.78−0.080.11
Week 60−0.28−0.05−0.65−1.010.09−0.09
  • ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity assessment; IgM-Rf, rheumatoid factor; SWS, stimulated whole salivary flow.